Peter Almond finished a trial for Donanemab in September having been on the drug for three years. Donanemab is one of the new ...

Production of biologic active ingredients at the site is scheduled to start in 2026. Part of the Limerick site's production capacity has been earmarked for donanemab, which was approved by the US ...

Treatment with donanemab (Kisunla) in patients with a baseline CDR-SB score of 2 who had low to medium tau would extend independence in IADLs by 13 months (95% CI 6-24 months). Alzheimer's ...

New research shows that lecanemab and donanemab can slow cognitive decline and extend patients' independence in daily activities. But with high costs and risks, are these treatments truly ...